Daily treatment with aspirin for five years or longer can effectively reduce the risk of colorectal cancer, according to a study published in The Lancet.
Researchers with the study said that although several studies already evidence aspirin's association to reduced risk of CRC, particularly in the gastrointestinal tract, proof in man is lacking. Results from the studies evidenced reduced risk of CRC, as well as lung, pancreatic, brain, prostate and esophageal cancer.
In eight trials involving more than 25,000 patients, the benefit of daily aspirin was apparent in all cancers after at the five-year follow-up. Evidence also showed there was no added benefit to taking aspirin doses of 75 milligrams or more.
Read the study about aspirin's association with CRC.
Read other coverage about colorectal cancer:
- Researchers Conduct Cost-Analysis Study of Colorectal Cancer Screening Modalities
- Researchers Investigate Possible Association of Inflammatory Markers and NSAIDs With CRC
- Tumor Location a Factor in Colorectal Cancer Mortality
Researchers with the study said that although several studies already evidence aspirin's association to reduced risk of CRC, particularly in the gastrointestinal tract, proof in man is lacking. Results from the studies evidenced reduced risk of CRC, as well as lung, pancreatic, brain, prostate and esophageal cancer.
In eight trials involving more than 25,000 patients, the benefit of daily aspirin was apparent in all cancers after at the five-year follow-up. Evidence also showed there was no added benefit to taking aspirin doses of 75 milligrams or more.
Read the study about aspirin's association with CRC.
Read other coverage about colorectal cancer:
- Researchers Conduct Cost-Analysis Study of Colorectal Cancer Screening Modalities
- Researchers Investigate Possible Association of Inflammatory Markers and NSAIDs With CRC
- Tumor Location a Factor in Colorectal Cancer Mortality